3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. |
100.00% |
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? |
97.50% |
Psorinum, the anti cancer miracle from India. |
91.47% |
Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. |
90.00% |
Clinical Investigations on Ukrain |
90.00% |
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. |
90.00% |
Is it time to test metformin in breast cancer clinical trials? |
90.00% |
The present state of antineoplaston research (1) |
90.00% |
NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell |
90.00% |
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy |
90.00% |
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. |
90.00% |
71 year old woman. Breast cancer with bone metastasis |
90.00% |
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti |
90.00% |
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
90.00% |
61 year old woman, Breast cancer with lymph, and lung metastasis |
90.00% |
Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer. |
90.00% |
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent |
90.00% |
Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, |
90.00% |
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. |
90.00% |
GcMAF-The cancer revolution from Japan |
87.50% |
Todoxin, the immune stimulant from Serbia |
86.36% |
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. |
85.00% |
Ukrain therapy of recurrent breast cancer with lung metastases (case report) |
80.00% |
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. |
80.00% |
Possible association between nanobacteria and malignant microcalcifications in breast cancer. |
80.00% |
A lipoxygenase inhibitor in breast cancer brain metastases. |
80.00% |
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. |
80.00% |
Response of brain metastases from breast cancer to megestrol acetate: a case report. |
80.00% |
Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled m |
80.00% |
Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador) |
80.00% |
Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort |
80.00% |
The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. |
80.00% |
82 year old woman. Breast cancer with lymph and bone metastasis. |
80.00% |
Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor–Positive and Hormone Receptor–Negative Breast Cancer |
80.00% |
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast ca |
80.00% |
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. |
80.00% |
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse |
80.00% |
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
Metformin in the treatment of Cancer |
77.00% |
Cancer Psychotherapy according to Dr. Frederick B Levenson |
76.00% |
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... |
75.00% |
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. |
70.00% |
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone |
70.00% |
Ukrain treatment in a patient with breast carcinoma |
70.00% |
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
70.00% |
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer |
70.00% |
Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial |
70.00% |
Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. |
70.00% |
Enhanced anticancer potential of encapsulated solid lipid nanoparticles of TPD: a novel triterpenediol from Boswellia serrata. |
70.00% |
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre |
70.00% |
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). |
70.00% |
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. |
65.00% |
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can |
63.33% |
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer |
60.00% |
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. |
60.00% |
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... |
60.00% |
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors. |
60.00% |
Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer with metronomic UFT + CP |
60.00% |
Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare |
60.00% |
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report) |
60.00% |
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel |
60.00% |
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). |
55.00% |
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera |
50.00% |
WITHDRAWN: Ovarian ablation for early breast cancer. |
50.00% |
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. |
50.00% |
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... |
50.00% |
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities |
50.00% |
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non |
50.00% |
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... |
50.00% |
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit |
50.00% |
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
50.00% |
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line |
50.00% |
Melatonin |
45.00% |
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. |
40.00% |
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. |
40.00% |
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. |
|
Breast Cancer Treatment |
|
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. |
|
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ |
|